TScan Therapeutics, Inc. TCRX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
TScan Therapeutics, Inc. (TCRX) is a healthcare company listed in the US with a market value of about $10M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$115M, a net margin of -2219.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 57% a year, a 5-year average ROIC of -33%.
About TScan Therapeutics
TScan Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $1M in 2020 to $10M in 2025, growth of about 56.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 440% over three years (dilution for shareholders). It spends 1106% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $5M | $10M | $3M | $21M | $14M | $10M | $1M |
| Net income | -$115M | -$130M | -$127M | -$89M | -$66M | -$49M | -$26M |
| Free cash flow | -$112M | -$140M | -$115M | -$65M | -$71M | -$59M | -$7M |
| EPS (diluted) | $-0.89 | $-2.00 | $-2.28 | $-2.72 | $-5.50 | $-8.34 | $-57.04 |
| Net margin | -2219.2% | -1256.8% | -4527.7% | -423.9% | -489.3% | -479.5% | -2408.0% |
| ROIC | — | -49.4% | -31.5% | -30.3% | -28.4% | -23.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $1.00, 523% above the current price; targets range from $1.00 to $1.00; the consensus rating is “Hold”; expected EPS is $-0.83 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does TScan Therapeutics pay a dividend?
Not currently.
Is TScan Therapeutics a good stock to buy?
We do not give buy or sell advice. TScan Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.